Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459519 | 0.86 | GP6 (0.65) | AGTR2AGTR1 | |
| SCHEMBL9651005 | 0.85 | AGTR2 (0.83) | AGTR2AGTR1 | |
| SCHEMBL1458408 | 0.85 | AGTR2 (0.67) | AGTR2AGTR1 | |
| SCHEMBL24360483 | 0.84 | AGTR1 (0.70) | AGTR2AGTR1ABCC4ABCB11PDE3B | |
| SCHEMBL8565334 | 0.83 | AGTR1 (0.73) | AGTR2AGTR1ABCC4ABCB11PDE3B | |
| SCHEMBL293 | 0.83 | AGTR1 (0.73) | AGTR2AGTR1ABCC4ABCB11PDE3B | |
| SCHEMBL8553367 | 0.83 | AGTR2 (0.68) | AGTR2AGTR1 | |
| SCHEMBL89 | 0.83 | AGTR1 (1.00) | AGTR2AGTR1 | |
| SCHEMBL29486822 | 0.83 | AGTR1 (1.00) | AGTR2AGTR1 | |
| SCHEMBL9468476 | 0.82 | AGTR1 (0.98) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2297113-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009134741-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885ABCC4 1438/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885ABCC4 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.